Buy Jubilant Life Sciences for target of Rs 496: Daljeet Kohli

648 views · Published 9 March 2016 · 14:59 · Indexed 12 November 2026

Channel: NDTV · 2016 · News & Politics

Watch on YouTube

Daljeet Kohli, head of research at IndiaNivesh Securities, says Jubilant Life Sciences' pharma business has started to perform and its margins are expected to return to a trajectory of 20-25 per cent in the coming quarters.

Watch more videos:  http://profit.ndtv.com/videos?yt   

Download the NDTV news app: 
https://play.google.com/store/apps/details?id=com.july.ndtv&referrer=utm_source%3Dyoutubecards%26utm_medium%3Dcpc%26utm_campaign%3Dyoutube

More from this channel